1. Home
  2. STE vs INCY Comparison

STE vs INCY Comparison

Compare STE & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo STERIS plc (Ireland)

STE

STERIS plc (Ireland)

HOLD

Current Price

$215.78

Market Cap

20.9B

Sector

Health Care

ML Signal

HOLD

Logo Incyte Corp.

INCY

Incyte Corp.

HOLD

Current Price

$96.46

Market Cap

17.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STE
INCY
Founded
1985
1991
Country
United States
United States
Employees
3700
N/A
Industry
Industrial Specialties
Biotechnology: Commercial Physical & Biological Resarch
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.9B
17.0B
IPO Year
2018
1994

Fundamental Metrics

Financial Performance
Metric
STE
INCY
Price
$215.78
$96.46
Analyst Decision
Buy
Buy
Analyst Count
5
21
Target Price
$275.20
$103.52
AVG Volume (30 Days)
681.4K
1.3M
Earning Date
05-11-2026
04-28-2026
Dividend Yield
1.19%
N/A
EPS Growth
62.73
4173.33
EPS
5.69
1.47
Revenue
$5,459,515,000.00
$3,394,635,000.00
Revenue This Year
$9.88
$10.44
Revenue Next Year
$6.32
$10.99
P/E Ratio
$38.45
$66.42
Revenue Growth
6.24
13.67
52 Week Low
$195.14
$63.93
52 Week High
$269.44
$112.29

Technical Indicators

Market Signals
Indicator
STE
INCY
Relative Strength Index (RSI) 50.90 48.40
Support Level $214.70 $93.17
Resistance Level $227.10 $103.11
Average True Range (ATR) 7.43 2.54
MACD 1.17 -0.24
Stochastic Oscillator 88.04 26.49

Price Performance

Historical Comparison
STE
INCY

About STE STERIS plc (Ireland)

Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Share on Social Networks: